Literature DB >> 18586190

Hormonal contraception and HIV-positive women: metabolic concerns and management strategies.

Julie Womack1, Susan Richman, Phyllis C Tien, Margaret Grey, Ann Williams.   

Abstract

As HIV-positive women live longer lives, and as testing for HIV becomes more routine, clinicians can expect to see more HIV-positive women in their practices. The need to be aware of management issues particular to this population becomes increasingly important. Metabolic dysregulation is a common, long-term complication associated with HIV and is one of the most difficult to manage. Hormonal contraception also is associated with metabolic dysregulation. As more HIV-positive women choose long-term, reversible contraception, the potential for concomitant and additive side effects, and the need for careful, proactive management strategies to avoid these complications, will become more important. This article reviews research detailing the metabolic dysfunction associated with hormonal contraception and with HIV-seropositivity. It highlights reasons for concern regarding the potential, although as yet theoretical, increased risk for metabolic dysfunction when hormonal contraception is used in the presence of HIV. Suggestions for management strategies for women living with HIV who choose to use hormonal contraception are presented. These strategies should be viewed as suggestions for management until substantitive research becomes available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586190      PMCID: PMC2776678          DOI: 10.1016/j.jmwh.2008.01.006

Source DB:  PubMed          Journal:  J Midwifery Womens Health        ISSN: 1526-9523            Impact factor:   2.388


  82 in total

1.  Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study.

Authors:  Fulya Kayikcioglu; Muzeyyen Gunes; Ozlem Ozdegirmenci; Ali Haberal
Journal:  Contraception       Date:  2006-03-23       Impact factor: 3.375

2.  Bone mineral density and depot medroxyprogesterone acetate.

Authors:  Paola Albertazzi; Mirella Bottazzi; Susan A Steel
Journal:  Contraception       Date:  2006-04-27       Impact factor: 3.375

3.  Fat distribution in women with HIV infection.

Authors: 
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

4.  Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.

Authors:  M van der Valk; J J Kastelein; R L Murphy; F van Leth; C Katlama; A Horban; M Glesby; G Behrens; B Clotet; R K Stellato; H O Molhuizen; P Reiss
Journal:  AIDS       Date:  2001-12-07       Impact factor: 4.177

Review 5.  Insulin resistance in the HIV-lipodystrophy syndrome.

Authors:  S Grinspoon
Journal:  Trends Endocrinol Metab       Date:  2001-11       Impact factor: 12.015

6.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

Review 7.  Interactions between antiepileptic drugs and hormonal contraception.

Authors:  Pamela Crawford
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.

Authors:  Mustafa A Noor; Tara Seneviratne; Francesca T Aweeka; Joan C Lo; Jean-Marc Schwarz; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

Review 9.  Sex steroids and insulin resistance.

Authors:  Callum Livingstone; Mary Collison
Journal:  Clin Sci (Lond)       Date:  2002-02       Impact factor: 6.124

10.  Endothelial function in HIV-infected persons.

Authors:  Anthony Solages; Joseph A Vita; David J Thornton; Jessica Murray; Timothy Heeren; Donald E Craven; C Robert Horsburgh
Journal:  Clin Infect Dis       Date:  2006-03-31       Impact factor: 9.079

View more
  2 in total

1.  Hormonal contraception and metabolic outcomes in women with or at risk for HIV infection.

Authors:  Julie A Womack; Rebecca Scherzer; Stephen R Cole; Kristopher Fennie; Ann B Williams; Margaret Grey; Howard Minkoff; Kathryn Anastos; Mardge H Cohen; Phyllis C Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

2.  Hormonal contraceptive use in HIV-infected women using antiretroviral therapy: A Systematic review.

Authors:  Julie A Womack; Gina Novick; Joseph L Goulet
Journal:  Open Access J Contracept       Date:  2015-05-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.